ArticleRheumatology (Oxford, England)2024
Identification and characteristics of patients with potential difficult-to-treat psoriatic arthritis: exploratory analyses of the Greek PsA registry.
Article in Rheumatology (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?Current opinion in rheumatology · 2026Review
- Cutaneous Manifestations in Psoriatic Arthritis: Phenotypes, Clinical Burden, and Therapeutic Implications.Rheumatology and therapy · 2026Review
- GLP-1 receptor agonists in osteoarthritis and psoriatic disease: the missing link between obesity and inflammation?Rheumatology international · 2026Review
- Article
- Complex-to-manage and treatment-refractory psoriatic arthritis in Argentina: real-world evidence from the RECCAPSO network.Clinical rheumatology · 2026Article
- Prevalence, outcomes, and predictive factors: a systematic literature review to inform the development of EULAR Points to Consider for the definition of Difficult-to-Manage and Treatment-Refractory psoriatic arthritis.EULAR rheumatology open · 2026Article
- Emerging Targets in Psoriatic Arthritis: Dual IL-17A/F and Selective TYK2 Inhibition in a Clinical Perspective.Mediterranean journal of rheumatology · 2026Review
- Beyond Clinical Trials: Experience with Bimekizumab in 3 Challenging Cases of Psoriatic Arthritis.Mediterranean journal of rheumatology · 2026Article
- Consensus definitions of complex-to-manage and treatment-refractory psoriatic arthritis: a GRAPPA initiative.Nature reviews. Rheumatology · 2026Review
- Clinical and ultrasonographic features preceding a difficult-to-treat phenotype in psoriatic arthritis: a retrospective real-world exploratory cohort study.Frontiers in immunology · 2026Article
- Real-World Effectiveness of Bimekizumab in Predominantly Difficult-to-Treat Patients with Psoriatic Arthritis Followed in a Combined Dermatology-Rheumatology Clinic: A 24-Week Multicenter Study.Rheumatology and therapy · 2025Article
- Clinical and Ultrasound Characteristics of a Difficult-to-Treat Psoriatic Arthritis Population.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Burden and determinants of multi-b/tsDMARD failure in psoriatic arthritis.Arthritis research & therapy · 2025Observational
- Difficult to Treat Psoriatic Arthritis: The Road So Far.Mediterranean journal of rheumatology · 2024Review
- Adherence, Fears, and Beliefs about Biologic Drugs in Rheumatoid Arthritis Patients: A North African Pilot Study.Mediterranean journal of rheumatology · 2024Article
- Difficult-to-Manage Axial Spondyloarthritis.Mediterranean journal of rheumatology · 2024Review
- Exploring the Cutting Edge: A Recap of EULAR & ACR 2023 Highlights for Spondyloarthritis, including Psoriatic Arthritis.Mediterranean journal of rheumatology · 2024Article
- The Spondyloarthritides: From Scientific and Therapeutic Immobility to the Forefront of Rheumatology Research.Mediterranean journal of rheumatology · 2024Article
- Difficult-to-treat psoriatic arthritis: refining the definition using a statistical model in a real-life cohort.Frontiers in medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors.
Funding
Abstract
objectiveTo present the characteristics of patients with potential difficult-to-treat (D2T) PsA.
methodsWe used data from the Greek multicentre registry of PsA patients. D2T PsA was defined as follows: patients with at least 6 months' disease duration, who have failed to at least one conventional synthetic DMARD and at least two biologic DMARDs/targeted synthetic DMARDs with a different mechanism of action and have either at least moderate disease activity (MODA) defined as DAPSA (Disease Activity index in PSoriatic Arthritis) >14, and/or are not at minimal disease activity (MDA). Demographic and clinical characteristics were compared between D2T and non-D2T PsA patients. In two sensitivity analyses, patients classified as D2T solely according to the MODA or MDA criterion were examined separately.
resultsAmong 467 patients included, 77 (16.5%) were considered D2T and 390 non-D2T PsA. Compared with non-D2T, patients with D2T PsA presented more commonly with extensive psoriasis (P < 0.0001) and were more likely to have higher BMI (P = 0.023) and a history of IBD (P = 0.026). In the MODA and MDA sensitivity analyses, 7.5% and 12.5% of patients were considered D2T, respectively. In both sensitivity analyses, extensive psoriasis was again identified as an independent variable for D2T PsA (P = 0.001 and P = 0.008, respectively). Moreover, female gender (P = 0.034) in the MODA analysis and axial disease (P = 0.040) in the MDA analysis were independent variables for D2T PsA.
conclusionDespite the availability of therapies, D2T PsA is common in real-life cohorts of patients with PsA and extensive psoriasis. High BMI, female gender, axial disease and history of IBD were also associated with D2T PsA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.